SOPHiA GENETICS Highlights Leadership Changes at 2026 Annual Meeting

SOPHiA GENETICS 2026 Annual General Meeting: Key Highlights

On June 22, 2026, SOPHiA GENETICS, a prominent player in Ai-driven precision medicine, held its Annual General Meeting (AGM). During this significant event, shareholders overwhelmingly endorsed all proposed agenda items. Notable among the decisions was the election of Dr. Jurgi Camblong as Executive Chairman of the Board, receiving an impressive 99.79% approval. Additionally, Ross Muken secured a position on the Board with 99.88% of votes and is expected to transition into the role of CEO starting July 1, 2026.

Strategic Leadership Transition

Dr. Jurgi Camblong, a co-founder of SOPHiA GENETICS, reflected on the journey of the company, expressing deep pride in the accomplishments over the past 15 years of his tenure as CEO. He emphasized the integral roles played by the teams and partners in growing the company's innovative healthcare solutions. Moving forward, Camblong aims to concentrate on long-term strategic development alongside Muken.

Incoming CEO Ross Muken commented on the momentum SOPHiA GENETICS is experiencing, fueled by increasing demand for data-driven medical technologies. He highlighted the company's mission to enhance patient care through its Ai-enabled platforms, indicating optimism regarding the opportunities that lie ahead. Muken expressed confidence in the team's ability to innovate and expand the company’s impact on a global scale.

Election of Board Members and Committee Chairs

Aside from the leadership transitions, several other board members were re-elected. Troy Cox, Tomer Berkovitz, Jean-Michel Cosséry, Kathy Hibbs, Didier Hirsch, and Vincent Ossipow all secured their positions for additional one-year terms until the 2027 AGM. Notably, Ross Muken was elected for his first term as a board member. Following the elections, Kathy Hibbs was also reappointed as Chair of the Compensation Committee, reaffirming her leadership role.

Financial Approvals and Governance

Shareholders approved the financial reports for the fiscal year 2025, affirming the appropriations, which included a net loss carry-forward. The AGM also saw the endorsement of the maximum board compensation for the year ahead and the re-election of PricewaterhouseCoopers as the company's external auditors.

In a move to strengthen corporate governance amidst leadership changes, a Lead Independent Director role was introduced. This position will rotate annually among chairs of independent board committees, ensuring that governance structures remain robust and effective.

Conclusion and Forward Outlook

The 2026 AGM represented a pivotal moment for SOPHiA GENETICS as it redefines its leadership and governance structures while adhering to the principles of transparency and accountability that are essential in the healthcare sector. With strong support from shareholders and a clear strategic vision, SOPHiA GENETICS is set to navigate future challenges while leading advancements in Ai-driven healthcare solutions. For more information, visit their official website at SOPHiAGENETICS.COM, and connect with them on LinkedIn for updates on their journey.

As the company embarks on this new chapter, the focus on innovation and patient care remains at the forefront, promising to deliver significant impacts for patients, providers, and the biopharmaceutical community.